Cardiovascular research institute, Isfahan University of Medical Sciences ARYA Atherosclerosis Journal 1735-3955 18 1 2022 01 01 Does second generation n-butyl cyanoacrylate embolization really smooth in greater saphenous vein closure? 1 6 31220 10.48305/arya.v18i1.2374 EN Seyhan Yilmaz Associate Professor, Department of Cardiovascular Surgery, Corlu Province Hospital, Tekirdag, Turkey 0000-0003-0865-0721 Feryaz Kiziltan Department of Cardiovascular Surgery, Umraniye Education and Research Hospital, Istanbul, Turkey 0000-0003-1113-4605 Sabür Zengin Department of Cardiovascular Surgery, Kirikkale Yuksek Ihtisas Hospital, Kirikkale, Turkey 0000-0003-4966-2681 Mehmet Kalender Department of Cardiovascular Surgery, Derince Education and Research Hospital, Kocaeli, Turkey 0000-0002-8984-4028 Isa Cam Department of Radiology, School of Medicine, Kocaeli University, Kocaeli, Turkey 0000-0001-9551-2364 Journal Article 2021 01 28  <strong>BACKGROUND: </strong>Cyanoacrylate (CA) has been used as an embolizing agent in the treatment of<br />greater saphenous vein (GSV) insufficiency in recent years and the results regarding the use of<br />this method have started to be published. To the best of our knowledge, the publications in<br />literature do not mention about a significant negative effect of endovenous CA (EVCA)<br />embolization. We aimed to evaluate the effects and undesirable events of this relatively new<br />treatment method and compare them with literature, using the follow-up data of our patients.<br /><strong>METHODS: </strong>Patients who had GSV insufficiency for at least 3 months and were treated with<br />EVCA embolization because of this disease were included in the study. Patients were excluded if<br />they had deep vein thrombosis (DVT), excessive tortuous GSV, and peripheral neuropathy.<br />Hospital archive records were reviewed and undesirable events like DVT, thrombophlebitis, and<br />pain related to this treatment procedure were recorded.<br /><strong>RESULTS: </strong>EVCA embolization procedure was performed in a total of 54 patients with an average<br />age of 49.36 ± 13.06 years for the purpose of treating GSV insufficiency. One patient was<br />observed to develop n-butyl CA (NBCA) extension of approximately 5 mm from saphenofemoral<br />junction (SFJ) to the main femoral vein and painful thrombophlebitic reaction was observed in<br />6 extremities at the first control examination.<br /><strong>CONCLUSION: </strong>In our opinion, while EVCA embolization is a treatment option with similar<br />success rates to endovenous thermal ablation (EVTA), it should be kept in mind that there may<br />be a possibility of developing thrombophlebitis and NBCA extension or thrombus extension to<br />the deep veins. https://arya.mui.ac.ir/article_31220_398fe2ec0161a64eb0ce33ece464fc06.pdf